Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects (EMPA)

What is the purpose of this trial?

The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date: 04/19/2017

End Date: 10/31/2018

Last Updated: 02/22/2018

Study HIC#: 2000020019

Get Involved

For more information about this study, contact:
Jennifer Tainsh

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image